Haleos Labs Limited
NSE: HALEOSLABS BSE: 540679Pharma
Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]
₹1,549
52W: ₹1050 — ₹1778
PE 25.7 · Book ₹684 · +126% vs bookMarket Cap₹468 Cr
Stock P/E25.7Price to Earnings
ROCE13.9%Return on Capital
ROE11.4%Return on Equity
Div. Yield0.1%Face Value ₹10
Strengths
- +Company has reduced debt.
Weaknesses
- −The company has delivered a poor sales growth of 5.35% over past five years.
- −Company has a low return on equity of 8.90% over last 3 years.
- −Dividend payout has been low at 3.00% of profits over last 3 years
Shareholding Pattern
Promoters72.1%
FIIs0%
DIIs0.3%
Public27.59%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 71.4% | 71.4% | 71.4% | 71.4% | 71.4% | 71.4% | 71.79%▲0.4 | 72.1%▲0.3 |
| FIIs | 0.01% | 0.02%▲0.0 | 0%▼0.0 | 0% | 0.03%▲0.0 | 0%▼0.0 | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0.03%▲0.0 | 0.29%▲0.3 | 0.3%▲0.0 |
| Public | 28.59% | 28.57%▼0.0 | 28.59%▲0.0 | 28.6%▲0.0 | 28.56%▼0.0 | 28.57%▲0.0 | 27.91%▼0.7 | 27.59%▼0.3 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 67.84 | 71.23 | 86.37 | 86.57 | 78.5 | 82.88 | 85.43 | 79.04 | 77.84 | 80.72 |
| Expenses | 58.36 | 62.21 | 75.56 | 72.8 | 66.71 | 69.81 | 79.83 | 68.21 | 67.04 | 69.16 |
| Operating Profit | 9.48 | 9.02 | 10.81 | 13.77 | 11.79 | 13.07 | 5.6 | 10.83 | 10.8 | 11.56 |
| OPM % | 13.97% | 12.66% | 12.52% | 15.91% | 15.02% | 15.77% | 6.56% | 13.7% | 13.87% | 14.32% |
| Net Profit | 3.12 | 3.31 | 5.93 | 6.46 | 6.01 | 6.23 | 2.68 | 5.16 | 4.98 | 5.41 |
| EPS ₹ | 10.32 | 10.95 | 19.61 | 21.37 | 19.88 | 20.61 | 8.86 | 17.07 | 16.47 | 17.89 |
AI Insights
Revenue Trend
TTM revenue at ₹323Cr, down 3% YoY. OPM at 12%.
Debt Position
Borrowings at ₹67Cr. Debt-to-equity ratio: 0.33x. Healthy balance sheet.
Capex Cycle
CWIP at ₹8Cr (5% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 0.3% (+0.30pp change). FIIs: 0% (+0.00pp change). Promoters hold 72.1%.
Margin & Efficiency
ROCE improving from 0% (Mar 2014) to 14% (Mar 2025). Working capital days: 57.
Valuation
PE 25.7x with 13.9% ROCE. Price is 126% above book value of ₹684. Dividend yield: 0.1%.
Recent Announcements
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 1 May - Postal ballot passed approving corporate guarantee for Mahi Drugs' ECB facility with RBL Bank, effective April 29, 2026.
- Encumbrance (Annual Disclosure) 8 Apr - Promoters disclosed no share encumbrance for FY2025-26.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr
- Annual Confirmation (Reclassification) 8 Apr - Suresh Babu Potluri confirms continued compliance for approved reclassification under SEBI Regulation 31A.
- Newspaper Publication (Postal Ballot) 31 Mar
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse